Clinical trials: Positive Axillary Lymph Node
Invasive Breast Cancer
Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node
Data from cohorts, prospective studies and one randomized trial (ASCOG Z0011) support the hypothesis that omission of additional axillary dissection in case of positive sentinel node has a limited impact on overall survival and…
- Trial name
- NCT01717131
- Testing
- Surgery for standard axillary node dissection, No axillary lymph node dissection
- Where
- France
- Volunteers
- 2,228 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer Invasive
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer
This study aims to explore the diagnostic performance of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with ER-positive breast cancer having clinically suspected or confirmed axillary lymph node…
- Trial name
- NCT06695039
- Testing
- Fluoroestradiol (18F)
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Asan Medical Center
Breast Cancer
Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast Cancer
The goal of this clinical trial is to evaluate the safety and feasibility of methylene blue single tracer-based extensive sentinel lymph node biopsy (ESLNB) and provide evidence for simplifying surgical procedures on the basis of…
- Trial name
- NCT07532096
- Testing
- ESLNB
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xijing Hospital
Breast Cancer by AJCC V8 Anatomic Stage, Breast Cancer
De-escalation of Axillary Dissection for Node-positive Breast Cancer
Recent studies have demonstrated the safety of de-escalation of nodal surgery for clinically node-positive breast cancer patients after a favorable response to neoadjuvant systemic therapy (NST).
- Trial name
- NCT07856160
- Testing
- TAD, ALND
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Breast Carcinoma Metastatic in Lymph Node, HER2 Positive Breast Carcinoma
Validation of TAD in HER-2 with More Than 2 Lymph Nodes
The main objective of the study is to validate the DAT technique in patients with Her2-positive breast cancer who have more than two positive axillary lymph nodes at diagnosis.
- Trial name
- DAD-HER2 (NCT06821490)
- Testing
- Targeted axillary dissection and subsequently a lymphadenectomy
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Breast Cancer
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
The efficacy of adjuvant chemotherapy is limited in patients with a high risk of recurrence. Also, for axillary positive node patients, optimum chemotherapy regimens are still under discussion.
- Trial name
- NCT00129922
- Testing
- paclitaxel, Fluorouracil, Epirubicin
- Where
- 64 sites in Spain
- Volunteers
- 1,289 people
- Sponsor
- Spanish Breast Cancer Research Group
Stage II Breast Cancer, Stage III Breast Cancer
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).
- Trial name
- NCT02115152
- Testing
- fluorouracil, capecitabine, cyclophosphamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
- Trial name
- NCT00004125
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive breast cancer overexpressing HER2
- Trial name
- NCT00615602
- Testing
- Docetaxel, Trastuzumab, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 489 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.
Since the introduction of sentinel node biopsy in breast cancer, it has become clear that its use is reliable and reproducible. Today, it is clinical routine to not remove further lymph nodes from the axilla (arm pit) in case the…
- Trial name
- NCT02240472
- Testing
- Omission of axillary clearance
- Where
- 33 sites in Denmark, Greece and 1 more
- Volunteers
- 2,766 people
- Sponsor
- Karolinska Institutet
Breast Cancer, Node-positive Breast Cancer
TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes
Due to high pathological complete remission (pCR) rates in both breast and lymph nodes (ypT0/Tis, ypN0) following neoadjuvant systemic therapy (NST) in many patients with initially clinically node-positive (cN+) breast cancer…
- Trial name
- SenTa2 (NCT05462457)
- Testing
- Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Kliniken Essen-Mitte
Breast Cancer
Docetaxel in Breast Cancer
Primary objective : To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer…
- Trial name
- NCT00312208
- Testing
- docetaxel, doxorubicin, cyclophosphamide, Docetaxel,doxorubicin, cyclophosphamide
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 3,299 people
- Sponsor
- Sanofi
Breast Cancer
POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer
POSNOC is a pragmatic, randomised, multicentre, non-inferiority trial. Aim For women with early stage breast cancer and one or two sentinel node macrometastases, to assess whether adjuvant therapy alone is no worse than adjuvant…
- Trial name
- POSNOC (NCT02401685)
- Testing
- Adjuvant therapy, Axillary treatment
- Where
- 50 sites in Australia, New Zealand and 1 more
- Volunteers
- 1,900 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Triple-negative Breast Cancer, HER2-positive Breast Cancer
CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
This is a prospective, single-center, non-randomized, non-controlled observational study.
- Trial name
- NCT04457700
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Peking University
Breast Cancer Invasive, Chemotherapy
Receptive Music Therapy Effects on Anxiety, Depression, QoL, and EGF, IL-8, and NfL During the Breast Cancer Treatment.
The goal of this clinical study is to investigate whether receptive music therapy can help women with breast cancer by reducing anxiety and depression symptoms, improving quality of life, and influencing specific analytes in…
- Conditions
- Breast Cancer Invasive, Chemotherapy, Breast Cancer Surgery, Breast Cancer
- Trial name
- NCT07483034
- Testing
- Music intervention
- Where
- Croatia
- Volunteers
- 90 people
- Sponsor
- Brigita Vilc
Location and Biopsy of Axillary Lymph Nodes
Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for CN+ Breast Cancer
To explore the feasibility of target biopsy of carbon nanoparticles labelled lymph node after neoadjuvant systemic therapy for cN+ breast cancer, and evaluate whether it can accurately predict axillary lymph node status after…
- Trial name
- NCT04482803
- Testing
- Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes
- Where
- China
- Volunteers
- 159 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002646
- Testing
- fenretinide, tamoxifen citrate
- Where
- 85 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Eastern Cooperative Oncology Group
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence.
- Trial name
- NCT04622319
- Testing
- DS-8201a, T-DM1
- Where
- 482 sites in United States, Argentina and 29 more
- Volunteers
- 1,600 people
- Sponsor
- Daiichi Sankyo
Breast Cancer Female
Axillary Sentinel or Targeted Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy in Node-positive Breast Cancer
This randomized phase II trial investigates the effectiveness of axillary sentinel or targeted lymph node biopsy alone after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial axillary metastasis.
- Trial name
- NCT05141630
- Testing
- sentinel lymph node biopsy or targeted axillary dissection alone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Breast Cancer
Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes
Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) is currently debatable. It is possible that the tumor response to chemotherapy may alter the lymphatic drainage thus causing lower SLN identification rate and…
- Trial name
- VSNBNAC (NCT01622478)
- Testing
- Sentinel lymph node biopsy, Neoadjuvant chemotherapy, complete axillary lymph node dissection
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Gangnam Severance Hospital